Infliximab (Remicade, Inflectra, Renflexis, Avsola)

Covered: infliximab products (Remicade, Inflectra, Renflexis, Avsola) for specified FDA‑approved non‑oncology indications and approved off‑label compendial uses (oncology indications excluded). Key requirements: indication‑specific prior‑therapy trials, age limits, and specialist prescription/consultation with documented diagnosis, prior treatments and durations, weight‑based dosing and infusion records (infusions ≥2 hours), documented clinical response for reauthorization, and adherence to specified initial and renewal approval durations.

"Approved Off-label Compendial Uses: Juvenile idiopathic arthritis"

Sign up to see full coverage criteria, indications, and limitations.